TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 448,500 shares, a drop of 56.0% from the May 31st total of 1,020,000 shares. Currently, 6.9% of the shares of the stock are sold short. Based on an average trading volume of 1,260,000 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Investors Weigh In On TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC bought a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of TransCode Therapeutics in a research report on Wednesday, May 29th.

TransCode Therapeutics Stock Performance

Shares of NASDAQ RNAZ traded down $0.01 during mid-day trading on Friday, reaching $1.01. 217,592 shares of the company were exchanged, compared to its average volume of 381,726. TransCode Therapeutics has a 52 week low of $0.42 and a 52 week high of $128.00. The company’s 50 day moving average price is $1.09 and its 200 day moving average price is $1.80.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.